HUP0101622A2 - Abacavir, lamivudin és zidovudin tartalmú homogén gyógyászati készítmények - Google Patents
Abacavir, lamivudin és zidovudin tartalmú homogén gyógyászati készítményekInfo
- Publication number
- HUP0101622A2 HUP0101622A2 HU0101622A HUP0101622A HUP0101622A2 HU P0101622 A2 HUP0101622 A2 HU P0101622A2 HU 0101622 A HU0101622 A HU 0101622A HU P0101622 A HUP0101622 A HU P0101622A HU P0101622 A2 HUP0101622 A2 HU P0101622A2
- Authority
- HU
- Hungary
- Prior art keywords
- abacavir
- lamivudine
- zidovudine
- medically
- preparation
- Prior art date
Links
- 229960004748 abacavir Drugs 0.000 title abstract 4
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 title abstract 4
- LHCOVOKZWQYODM-CPEOKENHSA-N 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 LHCOVOKZWQYODM-CPEOKENHSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008240 homogeneous mixture Substances 0.000 abstract 1
- 229960001627 lamivudine Drugs 0.000 abstract 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 229960002555 zidovudine Drugs 0.000 abstract 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány tárgyát gyógyászati készítmény képezi, amely i)biztonságos és gyógyászatilag hatásos mennyiségű abacavirt vagy ennekgyógyászatilag megfelelő származékát, ii) biztonságos ésgyógyászatilag hatásos mennyiségű lamivudint vagy ennek gyógyászatilagmegfelelő származékát, iii) biztonságos és gyógyászatilag hatásosmennyiségű zidovudint vagy ennek gyógyászatilag megfelelő származékátés iv) gyógyászatilag megfelelő glidánst, ami magnézium-sztearát,tartalmaz, ahol az abacavir, lamivudin és zidovudin 30-70 tömeg%-banvan jelen a készítmény össztömegére számítva, és a glidáns mennyisége0,05-5,0 tömeg% a készítmény össztömegére számítva. A találmányszerinti készítmény az abacavir, lamivudin és zidovudin homogénelegyét tartalmazza. A találmány szerinti vegyületelegy homogenitásáta megfelelő időpontban a hatóanyag elegyéhez adott glidáns biztosítja.A találmány szerinti készítmény eredményesen adható a humánimmunhiányt előidéző vírus (HIV) gátlására. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9809213.3A GB9809213D0 (en) | 1998-04-29 | 1998-04-29 | Pharmaceutical compositions |
| PCT/EP1999/002794 WO1999055372A1 (en) | 1998-04-29 | 1999-04-26 | Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0101622A2 true HUP0101622A2 (hu) | 2002-03-28 |
| HUP0101622A3 HUP0101622A3 (en) | 2003-09-29 |
Family
ID=10831228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0101622A HUP0101622A3 (en) | 1998-04-29 | 1999-04-26 | Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1083932A1 (hu) |
| JP (1) | JP2002512979A (hu) |
| KR (1) | KR20010043128A (hu) |
| CN (1) | CN1411380A (hu) |
| AP (1) | AP2000001971A0 (hu) |
| AU (1) | AU4135599A (hu) |
| BR (1) | BR9910071A (hu) |
| CA (1) | CA2330391A1 (hu) |
| EA (1) | EA200000997A1 (hu) |
| EE (1) | EE200000646A (hu) |
| GB (1) | GB9809213D0 (hu) |
| HR (1) | HRP20000732A2 (hu) |
| HU (1) | HUP0101622A3 (hu) |
| ID (1) | ID26955A (hu) |
| IL (1) | IL139181A0 (hu) |
| IS (1) | IS5675A (hu) |
| NO (1) | NO20005418L (hu) |
| NZ (1) | NZ507745A (hu) |
| PL (1) | PL343710A1 (hu) |
| SK (1) | SK16212000A3 (hu) |
| TR (1) | TR200003157T2 (hu) |
| WO (1) | WO1999055372A1 (hu) |
| ZA (1) | ZA200005922B (hu) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6875773B1 (en) | 1998-05-29 | 2005-04-05 | Ben M. Dunn | Combination therapy for treatment of FIV infection |
| AU4219799A (en) * | 1998-05-29 | 1999-12-13 | University Of Florida | Combination therapy for treatment of fiv infection |
| GB9820417D0 (en) * | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
| US7074417B2 (en) * | 2000-10-13 | 2006-07-11 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-viral product, use and formulation thereof |
| WO2003090762A1 (en) * | 2002-04-23 | 2003-11-06 | Lupin Limited | Long acting compositions comprising zidovudine and lamivudine |
| AR040242A1 (es) * | 2002-06-04 | 2005-03-23 | Glaxo Group Ltd | Composiciones farmaceuticas |
| CN100335125C (zh) * | 2003-06-03 | 2007-09-05 | 上海现代药物制剂工程研究中心 | 杀毒抗菌用长效干扰素喷鼻粉剂 |
| WO2006114709A1 (en) * | 2005-04-25 | 2006-11-02 | Aurobindo Pharma Limited | Pharmaceutical compositions of antiretrovirals |
| WO2007013047A2 (en) * | 2005-07-29 | 2007-02-01 | Ranbaxy Laboratories Limited | Water-dispersible anti-retroviral pharmaceutical compositions |
| ES2279707B1 (es) * | 2005-11-10 | 2008-06-01 | Combino Pharm, S.L. | Formulaciones orales que comprenden 3'-azidonucleosidos. |
| CN101878032A (zh) * | 2007-10-02 | 2010-11-03 | 埃默里大学 | 齐多夫定和针对hiv聚合酶中k65r突变选择的药剂的强力组合 |
| WO2009092002A1 (en) * | 2008-01-17 | 2009-07-23 | Duquesne University Of The Holy Spirit | Antiretroviral drug formulations for treatment of children exposed to hiv/aids |
| KR20170078868A (ko) | 2010-01-27 | 2017-07-07 | 비이브 헬쓰케어 컴퍼니 | 항바이러스 치료 |
| US20130115237A1 (en) | 2010-06-09 | 2013-05-09 | Vaccine Technologies, Incorporated | Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment |
| AU2013229274A1 (en) | 2012-03-05 | 2014-09-04 | Cipla Limited | Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine |
| JP2015534973A (ja) | 2012-10-23 | 2015-12-07 | シプラ・リミテッド | 抗レトロウイルス医薬組成物 |
| CN114404414A (zh) * | 2013-06-13 | 2022-04-29 | 阿克比治疗有限公司 | 用于治疗贫血症的组合物和方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115461A (en) * | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
| GB9622681D0 (en) * | 1996-10-31 | 1997-01-08 | Glaxo Group Ltd | Pharmaceutical compositions |
-
1998
- 1998-04-29 GB GBGB9809213.3A patent/GB9809213D0/en not_active Ceased
-
1999
- 1999-04-26 ID IDW20002479A patent/ID26955A/id unknown
- 1999-04-26 KR KR1020007012021A patent/KR20010043128A/ko not_active Application Discontinuation
- 1999-04-26 TR TR2000/03157T patent/TR200003157T2/xx unknown
- 1999-04-26 AU AU41355/99A patent/AU4135599A/en not_active Abandoned
- 1999-04-26 SK SK1621-2000A patent/SK16212000A3/sk unknown
- 1999-04-26 EP EP99924822A patent/EP1083932A1/en not_active Withdrawn
- 1999-04-26 NZ NZ507745A patent/NZ507745A/en unknown
- 1999-04-26 HU HU0101622A patent/HUP0101622A3/hu unknown
- 1999-04-26 EA EA200000997A patent/EA200000997A1/ru unknown
- 1999-04-26 CN CN99807983A patent/CN1411380A/zh active Pending
- 1999-04-26 BR BR9910071-1A patent/BR9910071A/pt not_active IP Right Cessation
- 1999-04-26 AP APAP/P/2000/001971A patent/AP2000001971A0/en unknown
- 1999-04-26 EE EEP200000646A patent/EE200000646A/xx unknown
- 1999-04-26 IL IL13918199A patent/IL139181A0/xx unknown
- 1999-04-26 WO PCT/EP1999/002794 patent/WO1999055372A1/en not_active Application Discontinuation
- 1999-04-26 PL PL99343710A patent/PL343710A1/xx unknown
- 1999-04-26 JP JP2000545569A patent/JP2002512979A/ja active Pending
- 1999-04-26 CA CA002330391A patent/CA2330391A1/en not_active Abandoned
-
2000
- 2000-10-20 IS IS5675A patent/IS5675A/is unknown
- 2000-10-23 ZA ZA200005922A patent/ZA200005922B/xx unknown
- 2000-10-27 NO NO20005418A patent/NO20005418L/no not_active Application Discontinuation
- 2000-10-27 HR HR20000732A patent/HRP20000732A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| GB9809213D0 (en) | 1998-07-01 |
| WO1999055372A1 (en) | 1999-11-04 |
| IL139181A0 (en) | 2001-11-25 |
| HUP0101622A3 (en) | 2003-09-29 |
| AU4135599A (en) | 1999-11-16 |
| KR20010043128A (ko) | 2001-05-25 |
| ID26955A (id) | 2001-02-22 |
| TR200003157T2 (tr) | 2001-01-22 |
| PL343710A1 (en) | 2001-08-27 |
| EA200000997A1 (ru) | 2001-06-25 |
| JP2002512979A (ja) | 2002-05-08 |
| CN1411380A (zh) | 2003-04-16 |
| SK16212000A3 (sk) | 2001-07-10 |
| BR9910071A (pt) | 2000-12-26 |
| NO20005418D0 (no) | 2000-10-27 |
| EE200000646A (et) | 2002-04-15 |
| CA2330391A1 (en) | 1999-11-04 |
| AP2000001971A0 (en) | 2000-12-31 |
| EP1083932A1 (en) | 2001-03-21 |
| HRP20000732A2 (en) | 2001-02-28 |
| ZA200005922B (en) | 2001-10-23 |
| NO20005418L (no) | 2000-11-29 |
| IS5675A (is) | 2000-10-20 |
| NZ507745A (en) | 2004-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0101622A2 (hu) | Abacavir, lamivudin és zidovudin tartalmú homogén gyógyászati készítmények | |
| KR960013435B1 (ko) | 바이러스 억제제 및 dsRNA를 함유하는 바이러스 감염질환 및 HIV 감염질환 치료용 조성물 | |
| UA40589C2 (uk) | Спосіб лікування людини, що страждає від вірусної інфекції, фармацевтична композиція, комбінація речовин для отримання ліків та фармацевтична комбінація | |
| RU2329050C2 (ru) | Комбинация ингибиторов цитохром-р450-зависимых протеаз | |
| HUP0102521A2 (hu) | Sztilbénszármazékot és platina koordinációs vegyületet tartalmazó daganatellenes szer | |
| BR9908488A (pt) | Composição farmacêutica de topiramato | |
| ATE330959T1 (de) | Allosterische adenosin-rezeptor-modulatore | |
| AP1849A (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| WO2002074056A3 (en) | Allosteric adenosine receptor modulators | |
| BG105173A (en) | Novel salt form of pantoprazole | |
| CA2446890A1 (en) | Deuterated 3-piperidinopropiophenones and pharmaceutical drugs containing these compounds | |
| DE69429964D1 (de) | Feste, therapeutische oder hygienische, mucoadhäsive Zusammensetzung zur Verabreichung durch Auftragen auf der Mund-schleimhaut oder der Nasen-schleimhaut | |
| HUP0301390A2 (hu) | Valzartánt tartalmazó orális gyógyászati készítmény | |
| HUP0003571A2 (hu) | 6,9-Hídkötésű eritromicin-származékok | |
| KR970705563A (ko) | 항바이러스제로서의 4-(2-아미노-6-(시클로프로필아미노)-9H-푸린-9-일)-2-시클로펜텐-1-메탄올 숙시네이트(4-(2-Amino-6-(Cyclopropylamino)-9H-Purin-9-yl)-2-Cyclopentene-1-Methanol Succinate as Antiviral Agent) | |
| BG101709A (en) | New applications of lysozyme dimer | |
| US3284298A (en) | Analgetic compositions and methods | |
| EA199900345A1 (ru) | Фармацевтические композиции, содержащие ламивудин и зидовудин | |
| HUP0002533A2 (hu) | Asztmaellenes gyógyszerhatóanyagok új kombinációja | |
| KR860003018A (ko) | 1-β-D-리보푸라노실-1,2,4-트리아졸-3-카르복사미드를 이용한 인체의 비루스성 질환의 의학적 치료방법 | |
| HUP0004701A2 (hu) | Új dezloratadin sók, az ezeket tartalmazó gyógyászati készítmények és eljárás azok előállítására | |
| HUP0402241A2 (hu) | Metformin és 4-oxo-butánsav kombinációját tartalmazó gyógyászati készítmény, és a készítmény alkalmazása diabétesz kezelésére | |
| HUP0402062A2 (hu) | Alkanoil-L-karnitin alkalmazása merevedési zavar kezelésére és ezt tartalmazó gyógyszerkészítmények | |
| ATE91890T1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
| HUP0401940A2 (hu) | Diabetikus neuropátia esetében alkalmazható gyógyszerkészítmény |